N/A
- Pharmaceuticals
- Bacterial Pneumonia Therapeutics Market
Bacterial Pneumonia Therapeutics Market
Bacterial Pneumonia Therapeutics Market: Global Industry Analysis and Forecast 2017 - 2025
Introduction
Pneumonia is an inflammation of the lung tissue; it is mainly caused by bacteria, virus, and fungi. However, pneumonia is most commonly caused by pathogenic bacteria—streptococcus pneumonia. If pneumonia is caused by bacteria such as Legionella pneumophila, Mycoplasma pneumonia and Chlamydia pneumonia, it is called atypical pneumonia. The most common symptoms of pneumonia are cough, fever, shaking chills and shortness of breath.
According to WHO, pneumonia is responsible for majority of deaths in children worldwide. In 2015, 16% of children deaths under 5years of age are due to pneumonia. Many antibiotics are currently available in the market to treat bacterial pneumonia conditions. However, antibiotics are becoming ineffective to treat bacterial pneumonia due to increase in resistance of bacteria. To prevent the resistance of the bacteria, companies are developing new generation antibiotic drugs.
Nabriva Therapeutics AG—biotechnology company—that involved in development of pleuromutilins, lefamulin drug, new class of antibiotics to treat community-acquired bacterial pneumonia (CABP) conditions. In April 2016, company initiated second Phase 3 clinical trial of lefamulin in patients with community-acquired bacterial pneumonia.
In June 2016, Astrazeneca’s, Zavicefta got market authorization in European Union to treat patients with hospital-acquired pneumonia (HAP) and ventilator associated pneumonia conditions. SetLance SRL involved in development of antimicrobial peptide M33, that showed encouraging in-vitro results in treating multi-drug resistant Klebsiella pneumonia bacteria and the research was funded government bodies. Furthermore, government organizations are also actively promoting research on pneumonia. PneumoNP is a research project funded by EU, to develop theragnostic system to treat resistant Gram-negative bacterial infections in lungs.
Increase in bacterial resistance of streptococcus bacteria, HIV associated pneumonia, rise in prevalence of pneumonia and government initiatives are major factors driving the growth of bacterial pneumonia therapeutics market over the forecast period. According to national statistics UK, in 2013, 5% of deaths in England and Wales are associated due to pneumonia and influenza. Lack of new drugs and improper diagnosis of pneumonia conditions are hindering the growth of this market over the forecast period.
The report covers exhaustive analysis on:
- Bacterial Pneumonia Therapeutics Market Segments
- Bacterial Pneumonia Therapeutics Market Dynamics
- Historical Actual Market Size, 2014 - 2016
- Bacterial Pneumonia Therapeutics Market Size & Forecast 2017 to 2025
- Bacterial Pneumonia Therapeutics Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Bacterial Pneumonia Therapeutics Market Drivers and Restraints
Regional analysis includes
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Report Highlights:
- Shifting Industry dynamics
- In-depth market segmentation
- Historical, current and projected industry size Recent industry trends
- Key Competition landscape
- Strategies of key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
